Welcome to our 2023 residency matches!

Welcome to Neurology!

Congratulations and welcome to our 2023-2024 residency intern class! We are so excited to welcome this diverse and fantastic group of trainees who are among the best of the best. The Adult Neurology cohort will begin PGY1 Preliminary Medicine year in July 2023 and PGY2 Neurology training in July 2024. The categorical Pediatric Neurology cohort […]

Equity for African Americans in Alzheimer’s disease (Links to an external site)

Washington University nurse Sarah Goddard administers an antibody infusion to Collins E. Lewis, MD, an associate professor emeritus of psychiatry, who has served for years as a healthy volunteer. He also is a member of the African American Advisory Board.

Alzheimer’s disease is like two deaths, said Stephanie Griffin, whose father died of the brain disease in 2015. “It’s horrific,” she said. “First, you watch them lose the ability to talk, to think, to do any of the things they used to do. And then, to see them pass because of it? It’s just … […]

Department of Neurology ranks No. 1 in NIH funding — again!

No. 1 in NIH funding

The Department of Neurology at Washington University School of Medicine in St. Louis has ranked No. 1 in NIH funding among all neurology departments for the second year in a row. Department leadership would like to thank everyone in the department for their hard work and outstanding contributions to research over the years. The Blue […]

Getting to know Neurology’s new vice chair for education, Doug Larsen

Doug Larsen

Education has been top-of-mind for Doug Larsen, MD, MEd, since the very beginning of his career. His medical school application focused on the physician as an educator. And pediatric neurology is essentially embedded in his DNA. “You could say I was exposed since birth!” Larsen, a professor of neurology & pediatrics at Washington University School […]

Amy Bain announced as Department of Neurology’s Staff Employee of the Quarter

Amy Bain

The Department of Neurology congratulates Neurology Clinical Office Supervisor Amy Bain for being awarded the Neurology Staff Employee of the Quarter for Q2 FY23. Bain was nominated by faculty and staff because she is a steadfast leader among the staff in the Section of Movement Disorders through constant change who is the go-to person for […]

Hope and healing for epilepsy (Links to an external site)

Neurologists look over EEG scans

We’ve all been there. You’re working on your mobile device, laptop or PC, when suddenly, something unusual happens. It might be just a screen flicker that quickly resolves itself. Or you have to reboot your machine. Or maybe you lose your work altogether. Either way, you may have just experienced how an electrical disturbance can […]

Sustainability key focus in Neuroscience Research Building construction (Links to an external site)

This rendering shows a large rooftop terrace on the third floor of the Neuroscience Research Building that can be used as a gathering place for employees and as an event space. Trees, such as elms, junipers and magnolias, will provide shade to help reduce heat during hotter months.

The Neuroscience Research Building under construction on the Washington University Medical Campus promises great discoveries in an environmentally friendly building that meets sustainability goals. The completed structure will contain energy-efficient, low-energy research freezers in laboratories; electric charging stations in the parking garage; and numerous other sustainability-focused elements.

That Blockbuster Alzheimer’s Drug? It’s Not a Cure (Links to an external site)

Signage is displayed on the exterior of Biogen Inc. headquarters in Cambridge, Massachusetts, U.S., on Friday, Aug. 5, 2016. Japan’s Eisai Co. said that an Alzheimer’s drug it is developing with Massachusetts-based Biogen Inc. will enter late-stage trials after getting the green light from the U.S. Food and Drug Administration. (Photographer: Bloomberg/Bloomberg)

Biogen Inc. and Eisai Co. caused a stir in September when they announced positive results in a late-stage trial for a closely watched Alzheimer’s drug, lecanemab. Doctors tempered their excitement, though, until they could scrutinize the full peer-reviewed data. That data arrived Tuesday night. And while it is stoking enthusiasm that physicians might soon be able […]